NCI-sponsored phase II study of [18f]fluoroestradiol (FES) as a marker of hormone sensitivity of metastatic breast cancer: Initial results

被引：2
|
作者：
Mankoff, D. A.
Linden, H. M.
Link, J.
Kurland, B. F.
Schubert, E. K.
Peterson, L.
Gadi, V. K.
Specht, J. M.
Shankar, L.
Eary, J. F.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA
[4] NCI, Canc Imaging Program, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11104
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Early results of an NCI-sponsored Phase II study of 18F-fluoroestradiol (FES) PET imaging of metastatic breast cancer (MBC)
    Peterson, Lanell
    Kurland, Brenda
    Linden, Hannah
    Link, Jeanne
    Schubert, Erin
    Gadi, Vijayakrishna
    Specht, Jennifer
    Eary, Janet
    Shankar, Lalitha
    Mankoff, David
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [2] [18F] fluoroestradiol (FES) PET as a predictive measure for endocrine therapy in women with newly diagnosed metastatic breast cancer
    Linden, Hannah
    Clark, Amy
    Fowler, Amy
    Novakova, Alena
    Mankoff, David
    Dehdashti, Farrokh
    CANCER RESEARCH, 2018, 78 (04)
  • [3] The heterogeneity of estrogen receptor (ER) expression in metastatic breast cancer is measured by [18F]-fluoroestradiol (FES) PET.
    Mankoff, DA
    Tewson, TJ
    Peterson, LM
    Stekhova, S
    Gralow, JR
    Livingston, RB
    Moe, RE
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 28P - 28P
  • [4] A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
    Peterson, Lanell M.
    Kurland, Brenda F.
    Schubert, Erin K.
    Link, Jeanne M.
    Gadi, V. K.
    Specht, Jennifer M.
    Eary, Janet F.
    Porter, Peggy
    Shankar, Lalitha K.
    Mankoff, David A.
    Linden, Hannah M.
    MOLECULAR IMAGING AND BIOLOGY, 2014, 16 (03) : 431 - 440
  • [5] A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
    Lanell M. Peterson
    Brenda F. Kurland
    Erin K. Schubert
    Jeanne M. Link
    V.K. Gadi
    Jennifer M. Specht
    Janet F. Eary
    Peggy Porter
    Lalitha K. Shankar
    David A. Mankoff
    Hannah M. Linden
    Molecular Imaging and Biology, 2014, 16 : 431 - 440
  • [6] Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
    Lanell M. Peterson
    Brenda F. Kurland
    Erin K. Schubert
    Jeanne M. Link
    V. K. Gadi
    Jennifer M. Specht
    Janet F. Eary
    Peggy Porter
    Lalitha K. Shankar
    David A. Mankoff
    Hannah M. Linden
    Molecular Imaging and Biology, 2019, 21 : 191 - 191
  • [7] 18F-fluoroestradiol (fes) and 18f-fluorodeoxyglucose (fdg) pet imaging in metastatic lobular breast cancer
    Manohar, Poorni
    Peterson, Lanell
    Wu, Vicky
    Jenkins, Isaac
    Muzi, Mark
    Specht, Jennifer
    Chen, Delphine
    Link, Jeanne
    Krohn, Kenneth
    Kinahan, Paul
    Mankoff, David
    Linden, Hannah
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Clinical production, stability studies and PET imaging with 16α-[18F] fluoroestradiol([18F]FES) in ER positive breast cancer patients
    Kumar, Piyush
    Mercer, John
    Doerkson, Courtney
    Tonkin, Katia
    McEwan, Alexander J. B.
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2007, 10 (02): : 256 - 265
  • [9] Early prediction of efficacy of endocrine therapy (ET) in metastatic breast cancer (MBC): Pilot study with [18F]fluoroestradiol-17β (18F-FES) PET/CT
    Gennari, A.
    Brain, E. G. C.
    Nanni, O.
    Harbeck, N.
    Cortes, J.
    De Censi, A.
    Piccardo, A.
    Alberini, J. L.
    Matteucci, F.
    Sacchetti, G.
    Ilhan, H.
    Monti, M.
    Wuerlestein, R.
    Saggia, C.
    Rossi, V.
    D'Avanzo, F.
    Maggiora, P. M.
    Iacozzi, M.
    Frassoldati, A.
    Boni, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S639 - S639
  • [10] Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study
    Mammatas, Lemonitsa H.
    Venema, Clasina M.
    Schroder, Carolina P.
    de Vet, Henrica C. W.
    van Kruchten, Michel
    Glaudemans, Andor W. J. M.
    Yaqub, Maqsood M.
    Verheul, Henk M. W.
    Boven, Epie
    van der Vegt, Bert
    de Vries, Erik F. J.
    de Vries, Elisabeth G. E.
    Hoekstra, Otto S.
    Hospers, Geke A. P.
    van Oordt, C. Willemien Menke-van
    EJNMMI RESEARCH, 2020, 10 (01)
12345